文献速递肝病

在2型糖尿病患者前瞻性队列中验证AGA临床诊疗路径和AASLD实践指导对非酒精性脂肪性肝病的诊断性能

Validation of AGA clinical care pathway and AASLD practice guidance for nonalcoholic fatty liver disease in a prospective cohort of patients with type 2 diabetes.
PubMed 文献 · Hepatology · 2023-10-20

本研究前瞻性纳入417例年龄≥50岁的2型糖尿病患者,评估AGA临床路径(FIB-4联合振动控制瞬时弹性成像)和AASLD实践指导(FIB-4联合ELF)对NAFLD的诊断性能。AGA路径假阴性率为3.3%,18%需专科转诊;AASLD路径假阴性率为4.5%,但50%需专科转诊;采用更高ELF切点后假阴性率4.9%,专科转诊降至27%。

要点

  • AGA路径(FIB-4联合VCTE)假阴性率3.3%,18%需专科转诊。
  • AASLD路径(FIB-4联合ELF)假阴性率4.5%,50%需专科转诊。
  • 提高ELF切点后假阴性率4.9%,专科转诊降至27%。

核心结论

  • 在2型糖尿病患者前瞻性队列中验证AGA临床路径显示假阴性率低,且避免了大部分患者的专科转诊。
  • AASLD的FIB-4联合ELF路径导致较高的专科转诊率,采用更高ELF切点后可改善,可能作为无VCTE设备的初级保健和内分泌诊所的替代方案。

研究设计与样本

  • 前瞻性研究纳入年龄≥50岁的2型糖尿病患者,进行标准化临床研究访视,包括MRI和超声评估肝脂肪和硬度以及ELF检测。
  • 共417例有FIB-4和MRE数据的2型糖尿病患者(36%为男性)纳入分析。

主要发现

  • NAFLD患病率为64%,12%存在晚期纤维化(MRE≥3.63 kPa)。
  • 应用AGA路径(FIB-4和VCTE),假阴性率为3.3%,18%符合专科转诊条件。
  • 应用AASLD路径(FIB-4+ELF),假阴性率为4.5%,50%符合专科转诊条件。
  • 采用更高ELF切点后,假阴性率相似为4.9%,但专科转诊降至27%。

关键数值与推荐

  • AGA路径:FIB-4和VCTE,假阴性率3.3%,专科转诊率18%。
  • AASLD路径:FIB-4+ELF,假阴性率4.5%,专科转诊率50%。
  • 更高ELF切点:假阴性率4.9%,专科转诊率27%。

临床怎么用

  • 在2型糖尿病患者中,AGA临床路径可识别低风险患者并避免大量专科转诊。
  • 无VCTE设备的初级保健和内分泌诊所可考虑使用FIB-4联合ELF路径,并采用更高ELF切点以减少专科转诊。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Recently, the American Gastroenterological Association and the American Association for the Study of Liver Diseases developed clinical pathways to evaluate populations at high risk for NAFLD. We assessed the diagnostic performance of the new guidance in a well-phenotyped cohort of patients with Type 2 diabetes mellitus (T2DM). APPROACH AND RESULTS: This prospective study enrolled patients age ≥50 years with T2DM. Participants underwent a standardized clinical research visit with MRI and ultrasound-based assessment of liver fat and stiffness and Enhanced Liver Fibrosis (ELF) testing. Of 417 participants (36% men) with T2DM with FIB-4 and MRE data, the prevalence of NAFLD was 64% and 12% had advanced fibrosis (MRE≥3.63 kPa). Applying the American Gastroenterological Association pathway of FIB-4 and vibration-controlled transient elastography, the false negative rate was 3.3% and 18% would qualify for specialty referral. Applying the FIB-4 + ELF American Association for the Study of Liver Diseases pathway, the false negative rate was 4.5%, but 50% would qualify for specialty referral. Applying higher ELF cut points improved the pathway, yielding a similar false negative rate of 4.9% but decreased specialty referral to 27%. CONCLUSION: Validation of the American Gastroenterological Association clinical pathway in a prospectively recruited cohort with T2DM revealed a low false negative rate and avoided specialty referral in a large percentage of patients. The American Association for the Study of Liver Diseases pathway with FIB-4 + ELF resulted in a high rate of specialty referral, which improved with the utilization of higher ELF cut points and may serve as an alternative for primary care and endocrinology clinics without access to vibration-controlled transient elastography.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Ajmera V, Tesfai K, Sandoval E, et al. Validation of AGA clinical care pathway and AASLD practice guidance for nonalcoholic fatty liver disease in a prospective cohort of patients with type 2 diabetes. Hepatology. 2023. PMID: 37862551. doi:10.1097/HEP.0000000000000635

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。